Evidence map›Paper›PMID 38519890›Full record

ArticleBMC pediatrics2024

Serum cholesterol level as a predictive biomarker for prognosis of Neuroblastoma.

Jie Min, Yi Wu, Shungen Huang, Yanhong Li, Xinjing Lv, Ruze Tang, He Zhao, Jian Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. NONO Maintains SREBP-Regulated Cholesterol Biosynthesis via RNA Binding in Neuroblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jie MinChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China.
Yi WuChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China.
Shungen HuangChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China.
Yanhong LiChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China.
Xinjing LvChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China.
Ruze TangChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China.
He ZhaoChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China. zh2021@suda.edu.cn.
Jian WangChildren's Hospital of Soochow University, Pediatric Research Institute of Soochow University, Suzhou, 215123, Jiangsu, China. jianwangsoochow@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroblastoma (NB), a type of solid tumor in children, has a poor prognosis. Few blood biomarkers can accurately predict the prognosis, including recurrence and survival, in children with NB. In this study, we found that the serum total cholesterol (Tchol) level was associated with the prognosis of patients through a retrospective study.

methodsMultivariate Cox regression model was used to identify the independent risk factors in the children with NB. Kaplan-Meier method was used to analyze the correlation between the common biomarkers, including the serum Tchol level, and the prognosis of the patients. ROC curves were used to predict the accuracy of the International Neuroblastoma Staging System (INSS) stage and Children's Oncology Group (COG) risk stratification after adding the serum Tchol level.

resultsCompared with the other patients, serum Tchol level was significantly increased in the relapsed and died patients (P < 0.05). Subsequently, serum Tchol level was found as an independent risk factor to affect the outcome of patients (P < 0.05). Finally, we added serum Tchol level into traditional stage and risk classification system to form the new INSS stage and COG risk classification system. It was found that the areas under the ROC curve (AUC) of recurrence-free survival in the new INSS stage and COG risk classification system were increased to 0.691 (95%CI: 0.535-0.847) and 0.748 (95%CI: 0.622-0.874), respectively. Moreover, the AUC areas of overall survival in the new INSS stage and COG risk classification system were increased to 0.722 (95%CI: 0.561-0.883) and 0.668 (95%CI: 0.496-0.819), respectively.

conclusionWe found that serum Tchol level, a clinical biomarker, is a risk factor for recurrence and death among the children with NB. The serum Tchol level could significantly increase the accuracy of the prediction for NB prognosis.

Indexed as

NeuroblastomaBiomarkersChildCholesterolHumansPrognosisRetrospective StudiesBiomarkersCholesterolNeuroblastomaPredictive biomarkerPrognosisSerum cholesterol

Identifiers

PMID38519890
PMCPMC10958969

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.